[ad_1]
New approaches to treatment against COVID-19, triggered by the SARS-CoV-2 coronavirus, are urgently needed.
Among the medications available, the Vides tonic Remdesivir (manufacturer Gilead Sciences), which is also used against Ebola, is one of those waiting.
However, in a first published randomized study, no significant advantage was found in treating seriously ill COVID-19 patients with remdesivir.
Even if there were indications that there could be a positive effect, this could not be clearly demonstrated.
“The first results of three randomized studies on the viral drug remdesivir, on which hopes for the treatment of COVID-19 are currently based, differ,” reports the German Medical Journal.
The NIAID assessment is, for example, in contradiction to a study already published in the journal “The Lancet”, which was unable to demonstrate any significant effect on the COVID-19 course to remdesivir.
Many options are currently being tested in treating infections with the novel SARS-CoV-2 coronavirus.
One of them is the use of virostatic remdesivir.
Despite the fact that the US National Institute of Allergy and Infectious Diseases. USA (NIAID) has already reported success with remdesivir from an ongoing study, there are still questions about its effectiveness.
The data available so far does not allow clear conclusions to be drawn.
US authorities report treatment was successful
However, according to NIAID, the study by the US National Institutes of Health. USA (NIH) found a clearer effect.
“Preliminary results show that patients who received remedesivir took 31 percent less time to recover than those who received a placebo,” said the NIAID.
Median recovery time after remedesivir treatment was eleven days, compared to 15 days after placebo administration.
A survival advantage was also hinted at.
For example, the death rate in the group that received remedesivir was eight percent, compared to 11.6 percent in the placebo group, reports the NIAID.
Remdesivir vs. COVID-19: Studies Provide Different Results
Antivirals are also used against Ebola
In a technical article https: // www.
bmj.
com / content / 369 / bmj.
However, m1798 from the British Medical Journal (BMJ), Professor of Clinical Pharmacology Robin Ferner of the University of Birmingham is extremely critical of the NIAID statement: “Expedited reviews or expedited publications are fine, but the hint that the Positive results will only benefit drug manufacturers.
“It also fits the picture that the US pharmaceutical agency FDA is already negotiating with the manufacturer Gilead Sciences about the fastest possible availability of the drug.
Although there is evidence of a positive effect of remdesivir on COVID-19 and this seems more likely if treatment is started early, a final evaluation based on the data available so far is not possible.
Although it is “desirable that treatments be evaluated quickly, what we need is reliable information,” emphasizes Professor Ferner.
(fp)
Important note:
This article contains general information only and should not be used for self-diagnosis or treatment.
It cannot replace a visit to the doctor.
